H Lundbeck pays research milestone to Vernalis
Under the contract, the companies will use Vernalis’ fragment and structure-based drug discovery platform against LRRK2. As per the terms of the deal, Vernalis is entitled to receive
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.